Terui Y - Search Results

1

Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.

Terui Y, Sakurai T, Mishima Y, Mishima Y, Sugimura N, Sasaoka C, Kojima K, Yokoyama M, Mizunuma N, Takahashi S, Ito Y, Hatake K. Terui Y, et al. Cancer Sci. 2006 Jan;97(1):72-9. doi: 10.1111/j.1349-7006.2006.00139.x. Cancer Sci. 2006. PMID: 16367924 Free article.

2

[Rituximab and hematological malignancy].

Hatake K, Mishima Y, Terui Y. Hatake K, et al. Among authors: terui y. Nihon Rinsho. 2004 Jul;62(7):1321-4. Nihon Rinsho. 2004. PMID: 15283150 Review. Japanese.

3

Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells.

Mishima Y, Terui Y, Sugimura N, Matsumoto-Mishima Y, Rokudai A, Kuniyoshi R, Hatake K. Mishima Y, et al. Among authors: terui y. Cancer Sci. 2007 Mar;98(3):364-72. doi: 10.1111/j.1349-7006.2007.00393.x. Cancer Sci. 2007. PMID: 17270026 Free article.

4

MEK-ERK is involved in SUMO-1 foci formation on apoptosis.

Utsubo-Kuniyoshi R, Terui Y, Mishima Y, Rokudai A, Mishima Y, Sugimura N, Kojima K, Sonoda Y, Kasahara T, Hatake K. Utsubo-Kuniyoshi R, et al. Among authors: terui y. Cancer Sci. 2007 Apr;98(4):569-76. doi: 10.1111/j.1349-7006.2007.00422.x. Epub 2007 Jan 31. Cancer Sci. 2007. PMID: 17284251 Free article.

5

[Recent progress in rituximab therapy and its resistance--how do we overcome?].

Hatake K, Yokoyama M, Terui Y. Hatake K, et al. Among authors: terui y. Gan To Kagaku Ryoho. 2007 Aug;34(8):1177-82. Gan To Kagaku Ryoho. 2007. PMID: 17687198 Review. Japanese.

6

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.

Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K. Ennishi D, et al. Among authors: terui y. Am J Hematol. 2008 Jan;83(1):59-62. doi: 10.1002/ajh.21022. Am J Hematol. 2008. PMID: 17712791 Free article.

7

Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors.

Mishima Y, Terui Y, Mishima Y, Taniyama A, Kuniyoshi R, Takizawa T, Kimura S, Ozawa K, Hatake K. Mishima Y, et al. Among authors: terui y. Cancer Sci. 2008 Nov;99(11):2200-8. doi: 10.1111/j.1349-7006.2008.00932.x. Epub 2008 Sep 22. Cancer Sci. 2008. PMID: 18823378 Free article.

8

Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.

Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K. Terui Y, et al. Clin Cancer Res. 2009 Apr 1;15(7):2523-30. doi: 10.1158/1078-0432.CCR-08-1403. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276251

9

[Rituximab resistance in B-cell lymphoma and its elimination].

Hatake K, Terui Y. Hatake K, et al. Among authors: terui y. Gan To Kagaku Ryoho. 2009 Apr;36(4):548-51. Gan To Kagaku Ryoho. 2009. PMID: 19381025 Japanese.

10

An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.

Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K. Mishima Y, et al. Among authors: terui y. Clin Cancer Res. 2009 May 15;15(10):3624-32. doi: 10.1158/1078-0432.CCR-08-1536. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417028 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page